• SENSEX
    NIFTY 50
Business

Ranitidine recall: Patient safety is our first priority, next step depends on test results, says GSK vice-president

Updated : September 27, 2019 01:25 PM IST

It is a Rs 200-crore focus brand in India; the company to find out a way to manage the financial impact of the recall.
It’s premature to give the financial impact because we are expecting some test results, says GSK Pharma VP and South Asia MD A Vaidheesh.
Ranitidine recall: Patient safety is our first priority, next step depends on test results, says GSK vice-president

You May Also Like

Live TV
Advertisement